Clinical TrialApr 28, 2026, 07:22 AM
BLRX: First Patient Dosed in Phase 1/2a GLIX1 Glioblastoma Study
AI Summary
BioLineRx Ltd. and Hemispherian AS announced the dosing of the first patient in their first-in-human, Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas. GLIX1 is an oral, first-in-class small molecule designed to activate TET2 and induce tumor DNA damage. The Phase 1 part of the trial will recruit up to 30 patients, with data anticipated in H1 2027.
Key Highlights
- First patient dosed in Phase 1/2a study of GLIX1 for glioblastoma.
- GLIX1 is an oral, first-in-class small molecule activating TET2.
- Phase 1 part to recruit up to 30 patients with recurrent/progressive GBM.
- Data from Phase 1 part anticipated in H1 2027.
- Study conducted under collaboration between BioLineRx and Hemispherian.
- Patient dosed at NYU Langone Health.
- Phase 2a expansion planned for newly diagnosed GBM and other cancers.
Price Impact
More from BLRX